Abstract
Get full access to this article
View all access options for this article.
References
1.
Johnson
MD
Campbell
LK
Campbell
RK
. Troglitazone: Review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus . Ann Pharmacother
1998 ;32 :337 –48 .
2.
Ghazzi
MN
Perez
JE
Antonucci
TK
Driscoll
JH
Huang
SM
Faja
BW
Cardiac and glycemic benefits of troglitazone treatment in NIDDM . Diabetes
1997 ;46 :433 –9 .
3.
Maggs
DG
Buchanan
TA
Burant
CF
Cline
G
Gumbiner
B
Hsueh
W
Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus . Ann Intern Med
1998 ;128 :176 –85 .
4.
Sutter
SL
Nolan
JJ
Wallace
P
Gumbiner
B
Olefsky
JM
. Metabolic effects of new oral hypoglycemic agents CS-045 in NIDDM subjects . Diabetes Care
1992 ;15 :447 –53 .
5.
Nolan
JJ
Ludvik
B
Beerdsen
P
Joyce
M
Olefsky
J
. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone . N Engl J Med
1995 ;331 :1189 –93 .
6.
Iwamoto
Y
Kuzuya
T
Matsuda
A
Awata
T
Kumakura
S
Inooka
G
Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM . Diabetes Care
1991 ;14 :1083 –6 .
7.
Iwamoto
Y
Kosaka
K
Kuzuya
T
Akanuma
Y
Shigeta
Y
Kaneko
T
. Effects of troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy . Diabetes Care
1996 ;19 :151 –6 .
8.
Schwartz
S
Raskin
P
Fonseca
V
Graveline
JF
. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus . N Engl J Med
1998 ;338 :861 –6 .
9.Product label . Rezulin (troglitazone) tablets . Morris Plains, NJ : Parke-Davis , December 1997 .
10.Data on file . Parke-Davis , Morris Plains, NJ .
11.
Inzucchi
SE
Maggs
DG
Spollett
GR
Page
SL
Rife
FS
Walton
BA
. Efficacy and metabolic effects of metformin and troglitazone in type 2 diabetes mellitus . N Engl J Med
1998 ;338 :867 –72 .